***Curis Inc.-Biorakete an der NASDAQ*** - 500 Beiträge pro Seite
eröffnet am 03.01.07 17:29:52 von
neuester Beitrag 14.02.07 13:39:18 von
neuester Beitrag 14.02.07 13:39:18 von
Beiträge: 11
ID: 1.103.144
ID: 1.103.144
Aufrufe heute: 0
Gesamt: 1.549
Gesamt: 1.549
Aktive User: 0
ISIN: US2312693094 · WKN: A3ETJD · Symbol: CRIS
16,510
USD
+3,25 %
+0,520 USD
Letzter Kurs 02.05.24 Nasdaq
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
3,3000 | +70,98 | |
1,7850 | +42,80 | |
1,7200 | +35,43 | |
1,0700 | +31,13 | |
5,8700 | +26,24 |
Wertpapier | Kurs | Perf. % |
---|---|---|
0,7500 | -16,67 | |
23,300 | -16,67 | |
0,5305 | -17,51 | |
3,5000 | -26,24 | |
11,500 | -29,23 |
da geht bald was! WKN:940909 www.curis.com
Curis Announces Key Management Promotions
Michael Gray Appointed COO and Dr. Changgeng Qian Promoted to the
Position of Vice President, Discovery and Preclinical Development
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 20, 2006--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, today announced recent promotions within its management team infrastructure. The changes were made to better align the management structure with Curis' ongoing strategy of deemphasizing early stage discovery research and seeking instead to develop proprietary later stage preclinical and, ultimately, clinical assets. The first such later stage program is a platform of proprietary cancer programs that target multiple validated cancer pathways. This platform is currently in preclinical testing and Curis expects to select the first lead clinical candidate in early 2007 and file an Investigational New Drug (IND) application during the second half of 2007.
Management Promotions
Michael P. Gray, who most recently held the position of Senior Vice President of Finance and Chief Financial Officer, will assume the additional role of Chief Operating Officer, while retaining the responsibilities and title of Chief Financial Officer. Gray will continue to have primary responsibility over a majority of Curis' administrative functions and will now have a greater role in aligning Curis' promising drug development programs with the company's overall corporate objectives and operating budget.
"Mike Gray has been an important part of the Curis team and has consistently demonstrated strong management and leadership skills during his tenure," said Dan Passeri, President and Chief Executive Officer of Curis. "He has provided solid financial and administrative oversight throughout his three years as Curis' Chief Financial Officer and was also instrumental in implementing various aspects of our recent entry into China. I will be looking to Mike to lead the coordination of the company's drug development and administrative efforts as we seek to move our drug programs into later stages of development in a highly effective and cost-efficient manner."
In addition, Curis recently promoted Dr. Changgeng Qian to the position of Vice President, Discovery and Preclinical Development. Dr. Qian joined Curis in 2001, bringing more than 25 years of academic and industrial experience in drug discovery, including pharmacokinetics, drug metabolism, efficacy evaluation, experimental disease model development and drug safety assessment. He has played key roles in the discovery and development of several drug candidates, including cancer and central nervous system indications at CytoMed, Inc., LeukoSite, Inc., and Millennium Pharmaceuticals, Inc.
Noted Passeri, "Dr. Qian brings tremendous experience and scientific leadership to his new role. He has been an invaluable asset to Curis, both in his guidance surrounding Curis' programs under collaboration, and in his leadership in directing Curis' wholly-owned and proprietary multi-targeted inhibitor (MTI) programs. We are extremely pleased to have someone of Dr. Qian's caliber leading these scientific efforts."
Curis Announces Key Management Promotions
Michael Gray Appointed COO and Dr. Changgeng Qian Promoted to the
Position of Vice President, Discovery and Preclinical Development
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 20, 2006--Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, today announced recent promotions within its management team infrastructure. The changes were made to better align the management structure with Curis' ongoing strategy of deemphasizing early stage discovery research and seeking instead to develop proprietary later stage preclinical and, ultimately, clinical assets. The first such later stage program is a platform of proprietary cancer programs that target multiple validated cancer pathways. This platform is currently in preclinical testing and Curis expects to select the first lead clinical candidate in early 2007 and file an Investigational New Drug (IND) application during the second half of 2007.
Management Promotions
Michael P. Gray, who most recently held the position of Senior Vice President of Finance and Chief Financial Officer, will assume the additional role of Chief Operating Officer, while retaining the responsibilities and title of Chief Financial Officer. Gray will continue to have primary responsibility over a majority of Curis' administrative functions and will now have a greater role in aligning Curis' promising drug development programs with the company's overall corporate objectives and operating budget.
"Mike Gray has been an important part of the Curis team and has consistently demonstrated strong management and leadership skills during his tenure," said Dan Passeri, President and Chief Executive Officer of Curis. "He has provided solid financial and administrative oversight throughout his three years as Curis' Chief Financial Officer and was also instrumental in implementing various aspects of our recent entry into China. I will be looking to Mike to lead the coordination of the company's drug development and administrative efforts as we seek to move our drug programs into later stages of development in a highly effective and cost-efficient manner."
In addition, Curis recently promoted Dr. Changgeng Qian to the position of Vice President, Discovery and Preclinical Development. Dr. Qian joined Curis in 2001, bringing more than 25 years of academic and industrial experience in drug discovery, including pharmacokinetics, drug metabolism, efficacy evaluation, experimental disease model development and drug safety assessment. He has played key roles in the discovery and development of several drug candidates, including cancer and central nervous system indications at CytoMed, Inc., LeukoSite, Inc., and Millennium Pharmaceuticals, Inc.
Noted Passeri, "Dr. Qian brings tremendous experience and scientific leadership to his new role. He has been an invaluable asset to Curis, both in his guidance surrounding Curis' programs under collaboration, and in his leadership in directing Curis' wholly-owned and proprietary multi-targeted inhibitor (MTI) programs. We are extremely pleased to have someone of Dr. Qian's caliber leading these scientific efforts."
Tue, Dec 26, 2006
FILING Report of unscheduled material events or corporate changes - Form 8-K
Wed, Dec 20, 2006
8:04 AM Curis Announces Key Management Promotions - Business Wire
FILING Report of unscheduled material events or corporate changes - Form 8-K
Thu, Nov 30, 2006
8:03 AM Curis to Present at Wall Street Analyst Forum Investor Conference - Business Wire
FILING Report of unscheduled material events or corporate changes - Form 8-K
Wed, Dec 20, 2006
8:04 AM Curis Announces Key Management Promotions - Business Wire
FILING Report of unscheduled material events or corporate changes - Form 8-K
Thu, Nov 30, 2006
8:03 AM Curis to Present at Wall Street Analyst Forum Investor Conference - Business Wire
Thu, Jan 04, 2007
FILING Annual statement of changes in beneficial ownership of securities - Form 5
wieso ist heute auf einmal so ein deutlich höheres volumen??
FILING Annual statement of changes in beneficial ownership of securities - Form 5
wieso ist heute auf einmal so ein deutlich höheres volumen??
Seitwärtsbewegung hält schon ziemlich lange an und die nachfrage im geld wird höher...
Börse
NASDAQ
Aktuell
1,34 USD
Zeit
26.01.07 19:11
Diff. Vortag
+3,88 %
Tages-Vol.
72.644,87
Gehandelte Stück
54.560
Geld
1,34
Brief
1,35
Zeit
26.01.07 19:11
Spread
0,74%
Geld Stk.
6.300
Brief Stk.
1.500
Schluss Vortag
1,29
Eröffnung
1,2801
Hoch
1,36
Tief
1,27
52W Hoch
2,82
52W Tief
0,95
Split
--
Börse
NASDAQ
Aktuell
1,34 USD
Zeit
26.01.07 19:11
Diff. Vortag
+3,88 %
Tages-Vol.
72.644,87
Gehandelte Stück
54.560
Geld
1,34
Brief
1,35
Zeit
26.01.07 19:11
Spread
0,74%
Geld Stk.
6.300
Brief Stk.
1.500
Schluss Vortag
1,29
Eröffnung
1,2801
Hoch
1,36
Tief
1,27
52W Hoch
2,82
52W Tief
0,95
Split
--
Nachfrage steigt! seit monaten seitwärtsbewegung, gute news auf deren internetseite...und und und...wann gehts los?
Börse
NASDAQ
Aktuell
1,39 USD
Zeit
31.01.07 19:05
Diff. Vortag
+5,30 %
Tages-Vol.
100.601,83
Gehandelte Stück
73.504
Geld
1,37
Brief
1,39
Zeit
31.01.07 19:16
Spread
1,44%
Geld Stk.
4.300
Brief Stk.
400
Börse
NASDAQ
Aktuell
1,39 USD
Zeit
31.01.07 19:05
Diff. Vortag
+5,30 %
Tages-Vol.
100.601,83
Gehandelte Stück
73.504
Geld
1,37
Brief
1,39
Zeit
31.01.07 19:16
Spread
1,44%
Geld Stk.
4.300
Brief Stk.
400
klettert und klettert in mini steps?
Börse
NASDAQ
Aktuell
1,47 USD
Zeit
02.02.07 15:30
Diff. Vortag
+2,80 %
Tages-Vol.
10.279,71
Gehandelte Stück
6.993
Geld
1,44
Brief
1,46
Börse
NASDAQ
Aktuell
1,47 USD
Zeit
02.02.07 15:30
Diff. Vortag
+2,80 %
Tages-Vol.
10.279,71
Gehandelte Stück
6.993
Geld
1,44
Brief
1,46
February 1, 2007 - 8:04 AM EST
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
CRIS 1.51 0.08
Today 5d 1m 3m 1y 5y 10y
Curis to Release Year End and Fourth Quarter 2007 Financial Results and Hold Conference Call on February 14, 2007
Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, will release its year end and fourth quarter financial results on Wednesday, February 14, 2007 before the market opens. The Company will also hold a conference call at 10:00 a.m. Eastern on the 14th to discuss the financial results, progress of its therapeutic product development programs, and additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
To access the live conference call, please call (800) 659-2032 from the United States and Canada or (617) 614-2712 from additional International locations, shortly before 10:00 A.M. The conference ID number is 81229487. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. EST, Wednesday, February 28, 2007. To access the replay, please call (888) 286-8010 from the United States and Canada or (617) 801-6888 from other locations and reference the conference ID number 50926099.
close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes
CRIS 1.51 0.08
Today 5d 1m 3m 1y 5y 10y
Curis to Release Year End and Fourth Quarter 2007 Financial Results and Hold Conference Call on February 14, 2007
Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, will release its year end and fourth quarter financial results on Wednesday, February 14, 2007 before the market opens. The Company will also hold a conference call at 10:00 a.m. Eastern on the 14th to discuss the financial results, progress of its therapeutic product development programs, and additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
To access the live conference call, please call (800) 659-2032 from the United States and Canada or (617) 614-2712 from additional International locations, shortly before 10:00 A.M. The conference ID number is 81229487. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. EST, Wednesday, February 28, 2007. To access the replay, please call (888) 286-8010 from the United States and Canada or (617) 801-6888 from other locations and reference the conference ID number 50926099.
Noch 1 Woche, dann kommen die Fakten auf den Tisch! Der Kurs ist seit Wochen stabil, sollten positive news kommen, kann es schnell rauf gehen, noch ist curis meiner meinung sehr günstig bei
February 1, 2007 - 8:04 AM EST
Curis to Release Year End and Fourth Quarter 2007 Financial Results and Hold Conference Call on February 14, 2007
Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, will release its year end and fourth quarter financial results on Wednesday, February 14, 2007 before the market opens. The Company will also hold a conference call at 10:00 a.m. Eastern on the 14th to discuss the financial results, progress of its therapeutic product development programs, and additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
To access the live conference call, please call (800) 659-2032 from the United States and Canada or (617) 614-2712 from additional International locations, shortly before 10:00 A.M. The conference ID number is 81229487. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. EST, Wednesday, February 28, 2007. To access the replay, please call (888) 286-8010 from the United States and Canada or (617) 801-6888 from other locations and reference the conference ID number 50926099.
About Curis, Inc.
Curis is a drug discovery and development company that is committed to leveraging its innovative signaling pathway drug technologies to create new medicines for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the Company is building upon its previous experiences in targeting signaling pathways in the areas of cancer, neurological disease, hair growth regulation and cardiovascular disease. For more information, please visit www.curis.com.
Curis, Inc.
Michael P. Gray, 617-503-6632
CFO/COO
mgray@curis.com
or
For Curis, Inc.
Jenny Viscarolasaga, 617-503-6658
Jenny@tworoadscommunications.com
Source: Business Wire (February 1, 2007 - 8:04 AM EST)
News by QuoteMedia
February 1, 2007 - 8:04 AM EST
Curis to Release Year End and Fourth Quarter 2007 Financial Results and Hold Conference Call on February 14, 2007
Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, will release its year end and fourth quarter financial results on Wednesday, February 14, 2007 before the market opens. The Company will also hold a conference call at 10:00 a.m. Eastern on the 14th to discuss the financial results, progress of its therapeutic product development programs, and additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
To access the live conference call, please call (800) 659-2032 from the United States and Canada or (617) 614-2712 from additional International locations, shortly before 10:00 A.M. The conference ID number is 81229487. Replay will be available approximately two hours after the completion of the call and through 5:00 P.M. EST, Wednesday, February 28, 2007. To access the replay, please call (888) 286-8010 from the United States and Canada or (617) 801-6888 from other locations and reference the conference ID number 50926099.
About Curis, Inc.
Curis is a drug discovery and development company that is committed to leveraging its innovative signaling pathway drug technologies to create new medicines for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the Company is building upon its previous experiences in targeting signaling pathways in the areas of cancer, neurological disease, hair growth regulation and cardiovascular disease. For more information, please visit www.curis.com.
Curis, Inc.
Michael P. Gray, 617-503-6632
CFO/COO
mgray@curis.com
or
For Curis, Inc.
Jenny Viscarolasaga, 617-503-6658
Jenny@tworoadscommunications.com
Source: Business Wire (February 1, 2007 - 8:04 AM EST)
News by QuoteMedia
sorry...bei:
Börse
NASDAQ
Aktuell
1,52 USD (49Mio Shares Outstanding)
Zeit
07.02.07 21:42
Diff. Vortag
+1,33 %
Tages-Vol.
172.751,60
Gehandelte Stück
114.853
Geld
1,51
Brief
1,53
Zeit
07.02.07 21:43
Spread
1,31%
Geld Stk.
6.500
Brief Stk.
100
Börse
NASDAQ
Aktuell
1,52 USD (49Mio Shares Outstanding)
Zeit
07.02.07 21:42
Diff. Vortag
+1,33 %
Tages-Vol.
172.751,60
Gehandelte Stück
114.853
Geld
1,51
Brief
1,53
Zeit
07.02.07 21:43
Spread
1,31%
Geld Stk.
6.500
Brief Stk.
100
Heute ist es so weit, schauen wir mal! ;=)
Tue, Feb 13, 2007
FILING An amendment to the SC 13G filing - Form SC 13G/A
FILING A statement of beneficial ownership of common stock by certain persons - Form SC 13G
Thu, Feb 01, 2007
8:04 AM Curis to Release Year End and Fourth Quarter 2007 Financial Results and Hold Conference Call on February 14, 2007 - Business Wire
Wed, Jan 31, 2007
8:10 AM Curis, Inc. Announces Dosing of First Patient in Hedgehog Antagonist Phase I Clinical Trial - Business
Tue, Feb 13, 2007
FILING An amendment to the SC 13G filing - Form SC 13G/A
FILING A statement of beneficial ownership of common stock by certain persons - Form SC 13G
Thu, Feb 01, 2007
8:04 AM Curis to Release Year End and Fourth Quarter 2007 Financial Results and Hold Conference Call on February 14, 2007 - Business Wire
Wed, Jan 31, 2007
8:10 AM Curis, Inc. Announces Dosing of First Patient in Hedgehog Antagonist Phase I Clinical Trial - Business
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
+1,19 | |
-11,56 | |
-0,27 | |
-3,19 | |
-2,05 | |
+1,42 | |
-1,28 | |
-1,03 | |
0,00 | |
+0,58 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
208 | ||
107 | ||
84 | ||
75 | ||
43 | ||
42 | ||
38 | ||
36 | ||
33 | ||
31 |